BTK and diffuse large B-cell lymphoma: In ABC-DLBCL that appear to be addicted to the BTK, as shown by high throughput experiments with siRNAs and sgRNA, the short PFS of 2 months achieved by ibrutinib in ABC-DLBCL in the 1/2 study pointed towards rapid acquisition of resistance.